Treatment options in irritable bowel syndrome

Farthing, 1995, Irritable bowel, irritable body, irritable brain?, British Medical Journal, 310, 171, 10.1136/bmj.310.6973.171 Whorwell, 1986, Non-colonic features of irritable bowel syndrome, Gut, 27, 37, 10.1136/gut.27.1.37 Gomborone, 1996, Prevalence of irritable bowel syndrome in chronic fatigue, Journal of the Royal College of Physics, 30, 512 Mayer, 2002, Evolving pathophysiologic models of functional gastrointestinal disorders, Gastroenterology, 122, 2032, 10.1053/gast.2002.33584 Mayer, 2000, The neurobiology of stress and gastrointestinal disease, Gut, 47, 861, 10.1136/gut.47.6.861 Gwee, 1996, Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, 150, 10.1016/S0140-6736(96)90341-4 Gwee, 1999, The role of psychological and biological factors in post infective gut dysfunction, Gut, 44, 400, 10.1136/gut.44.3.400 McKendrick, 1994, Irritable bowel syndrome—post Salmonella infection, Journal of Infection, 29, 1, 10.1016/S0163-4453(94)94871-2 McKendrick, 1996, Post Salmonella irritable bowel syndrome—5 year review, Journal of Infection, 32, 170, 10.1016/S0163-4453(96)91715-6 Neal, 1997, Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome; postal survey of patients, British Medical Journal, 314, 779, 10.1136/bmj.314.7083.779 Spiller, 2003, Postinfectious irritable bowel syndrome, Gastroenterology, 124, 1662, 10.1016/S0016-5085(03)00324-X Gwee, 1998, Evidence of inflammatory pathogenesis in post-infectious irritable bowel syndrome (abstr), Gastroenterology, 114, 758, 10.1016/S0016-5085(98)83103-X Spiller, 2000, Increased rectal mucosal enteroendocrine cells, T-lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, 804, 10.1136/gut.47.6.804 Bose, 2000, A comparison of 5-hydroxytryptamine staining in enterochronomaffin cells between irritable bowel syndrome and other gastrointestinal disorders, Gut, 47, 210 Farthing, 1978, Sensibility of the rectum to distension and the anorectal distension reflex in ulcerative colitis, Gut, 19, 64, 10.1136/gut.19.1.64 Klein, 1977, Controlled treatment trials in the irritable bowel syndrome: a critique, Gastroenterology, 95, 232, 10.1016/0016-5085(88)90319-8 Drossman, 1997, Irritable bowel syndrome: a technical review for practice guideline development, Gastroenterology, 112, 2120, 10.1053/gast.1997.v112.agast972120 Akehurst, 2001, Treatment of irritable bowel syndrome: a review of randomised controlled trials, Gut, 48, 272, 10.1136/gut.48.2.272 Francis, 1994, Bran and irritable bowel syndrome: time for reappraisal, Lancet, 344, 39, 10.1016/S0140-6736(94)91055-3 Bijkerk, 2004, Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 19, 245, 10.1111/j.0269-2813.2004.01862.x Efskind, 1996, A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome, Scandinavian Journal of Gastroenterology, 31, 463, 10.3109/00365529609006766 Poynard, 1994, Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 8, 499, 10.1111/j.1365-2036.1994.tb00322.x Poynard, 2001, Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 355, 10.1046/j.1365-2036.2001.00937.x Whorwell, 1984, Control trial of hypnotherapy in the treatment of severe refractory irritable bowel syndrome, Lancet, ii, 1232, 10.1016/S0140-6736(84)92793-4 Whorwell, 1987, Hypnotherapy in severe irritable bowel syndrome; further experience, Gut, 28, 423, 10.1136/gut.28.4.423 Guthrie, 1991, A brief psychotherapy with patients with refractory IBS, British Journal of Psychotherapy, 8, 175, 10.1111/j.1752-0118.1991.tb01174.x Guthrie, 1994, The difficult patient: treating the mind and the gut, European Journal of Gastroenterology and Hepatology, 6, 489, 10.1097/00042737-199406000-00007 Talley, 1996, Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials, American Journal of Gastroenterology, 91, 277 Jackson, 2000, Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis, American Journal of Medicine, 108, 65, 10.1016/S0002-9343(99)00299-5 Gorard, 1995, Effect of a tricyclic anti-depressant on small intestinal motility in health and in diarrhea-predominant irritable bowel syndrome, Digestive Diseases and Sciences, 40, 86, 10.1007/BF02063948 Gorard, 1994, 5 hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine uptake, Gut, 34, 496, 10.1136/gut.35.4.496 Farthing, 2002, Irritable bowel syndrome: new drugs and therapeutic horizons, 59 Farthing, 1991, 5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists, Scandinavian Journal of Gastroenterology, 26, 92, 10.3109/00365529109111236 Farthing, 1998, New drugs in the management of the irritable bowel syndrome, Drugs, 56, 11, 10.2165/00003495-199856010-00002 Farthing, 1999, Irritable bowel syndrome: new pharmaceutical approaches to treatment, Bailliere's Clinical Gastroenterology, 13, 461, 10.1053/bega.1999.0040 Sanger, 1996, 5-Hydroxytryptamine and functional bowel disorders, Neurogastroenterology and Motility, 8, 319, 10.1111/j.1365-2982.1996.tb00270.x Bearcroft, 1998, Post-prandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome, Gut, 42, 42, 10.1136/gut.42.1.42 Houghton, 2001, Increased platelet storesof 5-hydroxytryptamine (5-HT) in female patients with diarrhoea predominant irritable bowel syndrome (IBS), Gastroenterology, A636, 10.1016/S0016-5085(01)83162-0 Sanger, 1998, Different pathophysiological functions of 5-HT4 and 5-HT3 receptors in small and large intestine, Current Research in Serotonin, 3, 99 Sanger, 1998, Therapeutic applications of 5-HT4 receptor agonists and antagonists, 213 Prior, 1993, Reduction of rectal sensitivity and post-prandial motility by granisetron, 5-HT3 receptor antagonist, in patients with irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 175, 10.1111/j.1365-2036.1993.tb00087.x Hammer, 1993, Effect of a 5-HT3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 7, 543, 10.1111/j.1365-2036.1993.tb00131.x Goldberg, 1996, Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron), Digestion, 57, 478, 10.1159/000201377 Banner, 1995, Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity, British Journal of Pharmacology, 114, 558, 10.1111/j.1476-5381.1995.tb13263.x Camilleri, 2000, Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial, Lancet, 355, 1035, 10.1016/S0140-6736(00)02033-X Barbehenn, 2000, Alosetron for irritable bowel syndrome, Lancet, 356, 2009, 10.1016/S0140-6736(05)72978-0 Camilleri, 2001, A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome, Archives of Internal Medicine, 161, 1733, 10.1001/archinte.161.14.1733 Rabasseda, 1999, Cilansetron Drugs of the Future, 24, 475, 10.1358/dof.1999.024.05.489133 Camilleri, 2001, Review article: tegaserod, Alimentary Pharmacology and Therapeutics, 277, 10.1046/j.1365-2036.2001.00925.x Muller-Lissner, 2001, Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation, Alimentary Pharmacology and Therapeutics, 15, 1655, 10.1046/j.1365-2036.2001.01094.x Novick, 2002, A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation, Alimentary Pharmacology and Therapeutics, 16, 1877, 10.1046/j.1365-2036.2002.01372.x Kellow, 2003, An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome, Gut, 52, 671, 10.1136/gut.52.5.671 FDA talk paper, July 24, 2002. http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01160.html. Schoenfeld, 2004, Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials, Alimentary Pharmacology and Therapeutics, 19, 263, 10.1111/j.1365-2036.2004.01864.x Pimental, 2000, Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome, American Journal of Gastroenterology, 95, 3503, 10.1111/j.1572-0241.2000.03368.x Pimentel, 2004, A 14-day elemental diet is highly effective in normalizing lactulose breath test in IBS, Digestive Diseases and Science, 49, 10.1023/B:DDAS.0000011605.43979.e1 Niedzielin, 2001, A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome, European Journal of Gastroenterology and Hepatology, 13, 1143, 10.1097/00042737-200110000-00004 Quigley, 2002, Probiotics for the irritable bowel syndrome (IBS): A randomized, double-blind, placebo-controlled comparison of Lactobacillus and Bifidobacterium strains, Gastroenterology, 122 Hamilton-Miller, 2001, Probiotics in the management of irritable bowel syndrome: a review of clinical trials, Microbial Ecology Health Diseases, 3, 212, 10.1080/089106001753341282 Dunlop, 2003, Spiller R Randomized, double-blind placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 18, 77, 10.1046/j.1365-2036.2003.01640.x Madisch, 2004, Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled multi-centre trial, Alimentary Pharmacology and Therapeutics, 19, 271, 10.1111/j.1365-2036.2004.01859.x